|
|
Article: Genmab licenses MIF from Cytokine PharmaSciences.(macrophage migration inhibitory factor)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- November 27, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Danish biotechnology company Genmab AS says that it has licensed rights to a macrophage migration inhibitory factor (MIF) receptor from Cytokine PharmaSciences of the USA. MIF is a pro-inflammatory cytokine that is known to activate T cells and macrophages. Genmab said that it ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cytokine PharmaSciences Names Vidal F. de la Cruz, ...
PR Newswire;
December 9, 2004 ;
574 words
... ... Dec. 9 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the promotion ... Willson, President and CEO of Cytokine PharmaSciences. "Vidal has made an important ... President of Business Development." Cytokine PharmaSciences is a biopharmaceutical company ...
|
|